Hyper Lab Blog

In this Hyper Lab interview, José Antonio Costoya, Head of the Molecular Oncology Laboratory at the University of Santiago de Compostela CiMUS, talks about his research and the AI drug discovery platform Hyper Lab.

Here are three features that utilize Hyper Lab. You can prioritize experiments with hyper-binding, get drug structure suggestions with hyper-design, and see the binding structure of drugs and proteins with the 3D/2D viewer.

At the Drug Discovery Conference (DDC) 2024 and American Association of Cancer Research (AACR) 2024, held in April 2024, HITS unveiled Hyper Lab to the world. In this post, we will introduce a research scenario to demonstrate the use cases of Hyper Lab.

In this article, we analyze the posters submitted to DDC 2024, categorized by country, organization, and topic.

Summarize the drug discovery sessions that will be presented at AACR 2024.

We've summarized three important papers for AI drug discovery. These papers will help you understand the fundamentals of AI drug discovery and move forward with the latest research.

We've covered things to consider when defining a binding site during structure-based drug discovery research (SBDD).

Let's take a look at the trends in drug discovery papers accepted at ICLR 2024.

What's the biggest change in AlphaFold-latest compared to the last publicly available model, AlphaFold 2.3?

An analysis of global pharma M&A in 2023 shows that the post-pandemic market is poised for a revitalization.